{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:13:05Z","timestamp":1780593185739,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":4670,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.jpainsymman.2007.01.001","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T09:44:00Z","timestamp":1175247840000},"page":"462-472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Managing Metastatic Bone Pain: The Role of Bisphosphonates"],"prefix":"10.1016","volume":"33","author":[{"given":"Julie","family":"Gralow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.jpainsymman.2007.01.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"issue":"4 Suppl 11","key":"10.1016\/j.jpainsymman.2007.01.001_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0093-7754(01)90229-5","article-title":"Bone metastases: approaches to management","volume":"28","author":"Janjan","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib3","first-page":"895","article-title":"Therapy of metastatic bone pain","volume":"42","author":"Serafini","year":"2001","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2003.10.003","article-title":"Pain management in cancer patients with bone metastases remains a challenge","volume":"27","author":"Yau","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib6","first-page":"187","article-title":"Management of pain in skeletal metastases","volume":"312","author":"Twycross","year":"1995","journal-title":"Clin Orthop"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib7","first-page":"400","article-title":"Use of bisphosphonates for the palliative management of metastatic bone pain in the US","volume":"12","author":"Johnson","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib8","series-title":"Cancer pain relief and palliative care: Report of a WHO expert committee","author":"World Health Organization","year":"1990"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib9","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.jpainsymman.2007.01.001_bib10","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0960-9776(03)80162-5","article-title":"Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions","volume":"12","author":"Body","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib12","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"6 Suppl 21","key":"10.1016\/j.jpainsymman.2007.01.001_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/sonc.2002.37418","article-title":"Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid","volume":"29","author":"Saad","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","article-title":"Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro","volume":"28","author":"Benford","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib15","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0022-5347(05)65498-5","article-title":"Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates","volume":"166","author":"Berruti","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","article-title":"Morphometric evidence for bone resorption and replacement in prostate cancer","volume":"68","author":"Clarke","year":"1991","journal-title":"Br J Urol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib18","first-page":"41","article-title":"Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption","volume":"13","author":"Percival","year":"1987","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib19","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib21","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study","volume":"13","author":"Robertson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib26","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with i.v. pamidronate: results from a multinational randomized controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib28","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2007.01.001_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1569-9056(05)80576-7","article-title":"Long-term reduction of bone pain and skeletal morbidity with zoledronic acid in patients with prostate cancer and bone metastases","volume":"4","author":"Saad","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib33","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jpainsymman.2007.01.001_bib34","first-page":"S133","article-title":"Zoledronic acid reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer","volume":"88","author":"Kohno","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib35","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2007.01.001_bib36","first-page":"428","article-title":"The use of zoledronic acid in the treatment of painful bone metastases from prostate cancer","volume":"22","author":"Fulfaro","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.jpainsymman.2007.01.001_bib37","first-page":"iii223","article-title":"Zoledronic acid as supportive treatment in cancer patients with bone lesions: results of a prospective, open-label trial with pain intensity and analgesic consumption as primary outcome","volume":"15","author":"Kretzschmar","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib39","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized crossover study of community vs. hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1634\/theoncologist.11-7-841","article-title":"Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial","volume":"11","author":"Carteni","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib41","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib42","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomized, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib45","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib46","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.0902-4441.2003.132_1.x","article-title":"Is ibandronate effective in multiple myeloma?","volume":"71","author":"Body","year":"2003","journal-title":"Eur J Haematol"},{"issue":"2\u20133","key":"10.1016\/j.jpainsymman.2007.01.001_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","article-title":"The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats","volume":"191","author":"Pfister","year":"2003","journal-title":"Toxicology"},{"issue":"Suppl 3","key":"10.1016\/j.jpainsymman.2007.01.001_bib48","first-page":"iii226","article-title":"The risk of cumulative renal effects of intravenous (i.v.) bisphosphonates","volume":"15","author":"Pfister","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib49","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib51","first-page":"396","article-title":"Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer","volume":"11","author":"Ohlmann","year":"2003","journal-title":"Support Care Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.jpainsymman.2007.01.001_bib52","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","article-title":"High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer","volume":"1","author":"Heidenreich","year":"2003","journal-title":"Eur J Cancer"},{"issue":"4 Suppl 11","key":"10.1016\/j.jpainsymman.2007.01.001_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0093-7754(01)90235-0","article-title":"Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease","volume":"28","author":"Hillner","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib54","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0304-3959(00)00447-4","article-title":"Analgesic effect of bisphosphonates in mice","volume":"91","author":"Bonabello","year":"2001","journal-title":"Pain"},{"issue":"3 Suppl 1","key":"10.1016\/j.jpainsymman.2007.01.001_bib56","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.bone.2005.12.058","article-title":"Mechanisms of bone cancer pain relief with bisphosphonates","volume":"38","author":"Mantyh","year":"2006","journal-title":"Bone"},{"issue":"Suppl 5","key":"10.1016\/j.jpainsymman.2007.01.001_bib57","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/S1359-6349(03)90526-X","article-title":"Combination of ibandronate and radiotherapy in metastatic bone disease\u2014final results of a randomized phase II trial","volume":"1","author":"Micke","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib58","first-page":"401","article-title":"Palliative management of metastatic bone pain in Europe and Canada: the role of bisphosphonates","volume":"12","author":"McPartland","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib59","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0360-3016(99)00276-X","article-title":"Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians","volume":"47","author":"Cleeland","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00001813-199204000-00002","article-title":"Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases","volume":"3","author":"Neri","year":"1992","journal-title":"Anticancer Drugs"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2007.01.001_bib63","first-page":"75","article-title":"Intravenous clodronate for metastatic bone pain in breast cancer","volume":"37","author":"Shparik","year":"1996","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl","key":"10.1016\/j.jpainsymman.2007.01.001_bib64","first-page":"99","article-title":"Clodronate in the treatment of bone metastases secondary to breast cancer","volume":"77","author":"Falchi","year":"1991","journal-title":"Tumori"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2007.01.001_bib66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","article-title":"The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer","volume":"165","author":"Heidenreich","year":"2001","journal-title":"J Urol"},{"issue":"8 Suppl","key":"10.1016\/j.jpainsymman.2007.01.001_bib67","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.0.CO;2-V","article-title":"High dose pamidronate. Clinical and biochemical effects in metastatic bone disease","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392407000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392407000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:58:06Z","timestamp":1760129886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392407000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0885392407000255"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2007.01.001","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Metastatic Bone Pain: The Role of Bisphosphonates","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2007.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}